Ann: Dose Escalation in Phase 1 Clinical Trial of CHECKvacc, page-36

This announcement bodes well for the Vaxinia trial announced yesterday. The biggest hurdle of all new drug has always and will always be 'safety and tolerability'. This is why the FDA requires all trial to pass that first hurdle. Failing that, it will all grind to a halt! In this case, because it is such a new tech, the FDA has even demanded that they go slow with their patients recruitment.

Now, not only have they confirmed safety and tolerability, but also note efficacy even with this first very small dose. More importantly, no patients has died so far. After all, that first patient has been on this trial for more than 5 months already with such an aggressive TNBC curse! In fact, LC did say in one of her many interviews that anecdotal observation shows that the patients are doing very well. And that is on such a small first dose.

At this rate, one can safely say that we will be hit by many more such significant announcements before the year is out. IMU is the team that just keep on giving. I sincerely pray that Vaxinia works as it did in the lab. It would such great news to all the cancer patients in the world.